berrin pehlivan

Prof. Dr. Berrin Pehlivan
Oncologist

Languages: Turkish, French, English

Prof. Dr. Berrin Pehlivan since internship in Boston University, Radiation oncology department continue her career in radiation oncology direction. She attended to scientific research in many of leading institutes in Europe and continue to treat patients in Turkey.

1993, Graduated from Hacettepe University,Faculty of Medicine, Turkey
2001, MD speciality in Hacettepe University,Faculty of Medicine, Turkey 
2001 – 2004, Medical research assistant in Hacettepe University, Turkey
2004 – 2006, European cancerology program(DUERCC), France
2006 – 2007, Medical research assistant in Centre Hospitalier Vaudois, Switzerland
2007 – 2008, Visiting scientist in Proton Therapy Center, Paul Scherrer Institute, Switzerland
2008, Visiting scientist in Institute Curie Orsay Proton Therapy Center, France
2009 – 2010, Lecturer in Baskent University, Turkey
2010 – 2012, Assoc. Doc. Dr. in Akdeniz University, Radiation oncology
2011, Accreditation in Turkey Radiation Oncology Association
2012 – 2015, Doc. Dr. in Medstar Antalya Hospital, Radiation oncology
2015 – 2017, Doc. Dr. İn Medical Park Health Group, Bahcelievler Hospital, Radiation oncology
2017 – 2018, Prof. Dr. İn Medical Park Healtcare Group, Goztepe and Bahcelievler Hospital
2018, MD in BP own private clinic, Turkey

Memberships:
Turkish Radiation Association
Particle Therapy Cooperative Group (PTCOG)
Radiation Oncology Society
Turkish Business People Association UGIAD

Scientific Publications:
https://pubmed.ncbi.nlm.nih.gov/?term=Berrin+Pehlivan
 

Treatment of Brain Tumor

Prof. Dr.  Berrin PEHLİVAN

Treatment of brain tumor

Methods to treat brain tumors can be listed as radiation therapy, chemotherapy, surgical treatment, radio-surgery, thermotherapy, tumor treating fields (TTF) and immunotherapy. Treatment methods differentiated according to brain tumor type, volume and the other similar factors. If in the body occurred primary cancer and spread in relation to the brain it called secondary brain cancer. It would be convenient to apply different treatment methods to tumors of different origin that metastasize to the brain.